Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 September, 2018 05:12 IST
Lupin gets tentative USFDA approval for Testosterone gel
Source: IRIS | 17 Apr, 2018, 04.06PM
Comments  |  Post Comment

Pharma major Lupin announced that it has received tentative approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie Inc.'s AndraGel®, 1.62%.

Lupin's Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) is the generic equivalent of AbbVie Inc.'s AndroGel®, 1.62%. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).

Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation) had annual sales of approximate USD 956.9 million in the US (IQVIA MAT January 2018).

Shares of the company gained Rs 22.95, or 2.94%, to settle at Rs 804.30. The total volume of shares traded was 128,567 at the BSE (Tuesday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
ITD Cementation India wins orders worth Rs 8.45 bn - 21-Sep-2018 15:44
Emami Paper Mills to invest around Rs 20 bn in Gujarat - 21-Sep-2018 15:03
Tijaria Polypipes receives single order worth Rs 353 mn - 21-Sep-2018 13:13
Infosys to open technology and innovation hub in Arizona - 21-Sep-2018 13:08
Pennar Group bags orders worth Rs 1.81 bn - 21-Sep-2018 13:05
TCS recognized as leader in finance and accounting digital augmentation suite - 21-Sep-2018 12:30
Sun Pharma announces Australian TGA approval of ILUMYA - 21-Sep-2018 12:06
Fitch revises outlook on Tata Motors to negative; affirms at BB+ - 21-Sep-2018 10:55
SBI, QCI sign MoU on Zero Defect Zero Effect Certification for MSMEs - 21-Sep-2018 09:50
TCS partners with The Training Room, UK - 21-Sep-2018 09:46
Strides Pharma Science gets ACCC approval for merger of Arrow and Apotex Australia - 20-Sep-2018 10:15
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer